One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Serum Monitoring of Recurrence in Post-Operative Crohn’s Disease: Have We Arrived?
Robert Battat
doi : 10.1093/ecco-jcc/jjac077
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1795–1796
Non-invasive Serological Monitoring for Crohn’s Disease Postoperative Recurrence
Amy L Hamilton, Peter De Cruz, Emily K Wright, Thierry Dervieux, Anjali Jain, Michael A Kamm
doi : 10.1093/ecco-jcc/jjac076
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1797–1807
Crohn’s disease recurs after intestinal resection. This study evaluated accuracy of a new blood test, the Endoscopic Healing Index [EHI], in monitoring for disease recurrence.
Safety of Ustekinumab and Vedolizumab During Pregnancy—Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study
Katarina Mitrova, Barbora Pipek, Martin Bortlik, Ludek Bouchner, Jan Brezina, Tomas Douda, Tomas Drasar, Pavel Klvana, Pavel Kohout, Vaclav Leksa, Petra Minarikova, Ales Novotny, Pavel Svoboda, Jan Skorpik, Jan Ulbrych, Marek Veinfurt, Blanka Zborilova, Milan Lukas, Dana Duricova, Czech IBD Working Group
doi : 10.1093/ecco-jcc/jjac086
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1808–1815
Evidence on the safety of newer biologics during pregnancy is limited. We aimed to assess the safety of ustekinumab and vedolizumab treatment during gestation on pregnancy and infant outcome. Furthermore, we evaluated the placental transfer of these agents.
Biologic Therapy for Budesonide-refractory, -dependent or -intolerant Microscopic Colitis: a Multicentre Cohort Study from the GETAID
Grégoire Boivineau, Camille Zallot, Franck Zerbib, Laurianne Plastaras, Aurélien Amiot, Lucile Boivineau, Stéphane Koch, Laurent Peyrin-Biroulet, Lucine Vuitton
doi : 10.1093/ecco-jcc/jjac089
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1816–1824
Budesonide remains the backbone therapy for microscopic colitis [MC]; however, relapses are frequent, and some patients are intolerant or dependent. Anti-TNF therapy is increasingly used to treat these patients, but available evidence is still limited. The aim of this study was to evaluate the effectiveness and safety of anti-TNF therapy in MC patients failing budesonide.
Increased Risk of Non-conventional and Invisible Dysplasias in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease
Ruth Zhang, Gregory Y Lauwers, Won-Tak Choi
doi : 10.1093/ecco-jcc/jjac090
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1825–1834
Patients with primary sclerosing cholangitis and inflammatory bowel disease [termed PSC-IBD] have a higher risk of developing colorectal neoplasia than those with IBD alone.
Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children
Zheng Liu, Mette Julsgaard, Xiao Zhu, Jennifer Martin, Murray L Barclay, Noel Cranswick, Peter R Gibson, Richard B Gearry, Janine van der Giessen, Susan J Connor, Ourania Rosella, Anne Grosen, Catherine Toong, Emma Flanagan, Jantien W Wieringa, C Janneke van der Woude, Sally J Bell, The CARINA Study Group
doi : 10.1093/ecco-jcc/jjac093
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1835–1844
For infants exposed in utero to anti-tumour necrosis factor-α [TNF] medications, it is advised that live-attenuated vaccinations be postponed until the drug is cleared, but little is known about time to clearance. To minimize delays before live-attenuated vaccination can be given, we aimed to develop a pharmacokinetic model to predict time-to-clearance in infants exposed during pregnancy.
Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case Series
Brigida Barberio, Edoardo Savarino, Bram Verstockt, Mathurin Fumery, Daniela Pugliese, Lorenzo Bertani, Andrea Buda, Gabriele Dragoni, Idan Goren, Ido Laish, Antonino Spinelli, Niels Teich, Marie Truyens, Pierre Ellul
doi : 10.1093/ecco-jcc/jjac094
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1845–1852
Hereditary colorectal cancer syndromes [HCCS] are rare polyposis or nonpolyposis syndromes with a higher risk of developing colorectal cancer [CRC]. Coexisting inflammatory bowel disease [IBD], including ulcerative colitis [UC] and Crohn’s disease [CD], with HCCS is exceedingly rare and presumably increases the risk of early-onset CRC.
Segmental Versus Total Colectomy for Crohn’s Disease in the Biologic Era: Results From The SCOTCH International, Multicentric Study
Gianluca Pellino, Matteo Rottoli, Michela Mineccia, Alice Frontali, Valerio Celentano, Francesco Colombo, Caterina Baldi, Sandro Ardizzone, Marc Martà Gallostra, Eloy EspÃn-Basany, Alessandro Ferrero, Yves Panis, Gilberto Poggioli, Gianluca M Sampietro
doi : 10.1093/ecco-jcc/jjac096
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1853–1861
The extent of resection in colonic Crohn’s disease [cCD] is still a topic of debate, depending on the number of locations, the risk of recurrence and permanent stoma, and the role of medical therapy.
Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease
Akhilesh Swaminathan, Grace M Borichevsky, Teagan S Edwards, Esther Hirschfeld, Thomas C Mules, Chris M A Frampton, Andrew S Day, Mark B Hampton, Anthony J Kettle, Richard B Gearry
doi : 10.1093/ecco-jcc/jjac098
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1862–1873
Inflammatory bowel disease [IBD], consisting of Crohn’s disease [CD] and ulcerative colitis [UC], is a relapsing-remitting illness. Treat-to-target IBD management strategies require monitoring of gastrointestinal inflammation. This study aimed to investigate faecal myeloperoxidase [fMPO], a neutrophil granule enzyme, as a biomarker of IBD activity.
Patient-reported Outcomes: the ICHOM Standard Set for Inflammatory Bowel Disease in Real-life Practice Helps Quantify Deficits in Current Care
Darren Wong, Lawrence Matini, Andrey Kormilitzin, Ramona Kantschuster, Daniel Martin Simadibrata, Sara Lyden, Jean Wilson, Oliver A Brain, Rebecca Palmer, Tim Ambrose, Jack Satsangi, Matthew South, John Geddes, Keith Bodger, Simon P L Travis, Alissa Walsh
doi : 10.1093/ecco-jcc/jjac099
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1874–1881
Patient-reported outcome measures [PROMs] are key to documenting outcomes that matter most to patients and are increasingly important to commissioners of health care seeking value. We report the first series of the ICHOM Standard Set for Inflammatory Bowel Disease [IBD].
Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
Henit Yanai, Anna Kagramanova, Oleg Knyazev, João Sabino, Shana Haenen, Gerassimos J Mantzaris, Katerina Mountaki, Alessandro Armuzzi, Daniela Pugliese, Federica Furfaro, Gionata Fiorino, David Drobne, Tina Kurent, Sharif Yassin, Nitsan Maharshak, Fabiana Castiglione, Roberto de Sire, Olga Maria Nardone, Klaudia Farkas, Tamas Molnar, Zeljko Krznaric, Marko Brinar, Elena Chashkova, Moran Livne Margolin, Uri Kopylov, Cristina Bezzio, Ariella Bar-Gil Shitrit, Milan Lukas, MarÃa Chaparro, Marie Truyens, Stéphane Nancey, Triana Lobaton, Javier P Gisbert, Simone Saibeni, Péter Bacsúr, Peter Bossuyt, Julien Schulberg, Frank Hoentjen, Chiara Viganò, Andrea Palermo, Joana Torres, Joana Revés, Konstantinos Karmiris, Magdalini Velegraki, Edoardo Savarino, Panagiotis Markopoulos, Eftychia Tsironi, Pierre Ellul, Cristina Calviño Suárez, Roni Weisshof, Dana Ben-Hur, Timna Naftali, Carl Eriksson, Ioannis E Koutroubakis, Kalliopi Foteinogiannopoulou, Jimmy K Limdi, Eleanor Liu, Gerard SurÃs, Emma Calabrese, Francesca Zorzi, RafaÅ‚ Filip, Davide Giuseppe Ribaldone, Yifat Snir, Idan Goren, Hagar Banai-Eran, Yelena Broytman, Hadar Amir Barak, Irit Avni-Biron, Jacob E Ollech, Iris Dotan, Maya Aharoni Golan
doi : 10.1093/ecco-jcc/jjac100
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1882–1892
Endoscopic-post-operative-recurrence [ePOR] in Crohn’s disease [CD] after ileocecal resection [ICR] is a major concern. We aimed to evaluate the effectiveness of early prophylaxis with biologics and to compare anti-tumour necrosis factor [anti-TNF] therapy to vedolizumab [VDZ] and ustekinumab [UST] in a real-world setting.
PU.1-driven Th9 Cells Promote Colorectal Cancer in Experimental Colitis Models Through Il-6 Effects in Intestinal Epithelial Cells
Katharina Gerlach, Vanessa Popp, Stefan Wirtz, Ragheed Al-Saifi, Miguel Gonzalez Acera, Raja Atreya, Theresa Dregelies, Michael Vieth, Stefan Fichtner-Feigl, Andrew N J McKenzie, Frank Rosenbauer, Benno Weigmann, Markus F Neurath
doi : 10.1093/ecco-jcc/jjac097
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1893–1910
Colorectal cancer [CRC] is one of the most frequent malignancies, but the molecular mechanisms driving cancer growth are incompletely understood. We characterised the roles of the cytokine IL-9 and Th9 cells in regulating CRC development.
Intestinal Epithelial Responses to IL-17 in Adult Stem Cell-derived Human Intestinal Organoids
Chansu Lee, Joo Hye Song, Yeo-Eun Cha, Dong Kyung Chang, Young-Ho Kim, Sung Noh Hong
doi : 10.1093/ecco-jcc/jjac101
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1911–1923
Th17 cells and their signature cytokine, interleukin-17A [IL-17], are considered as the main pathogenic factors in inflammatory bowel diseases [IBDs]. However, IL-17 neutralising antibodies, a theoretically curative medication for IBDs, paradoxically aggravated intestinal inflammation. The mechanisms by which IL-17 mediates the protective and pathological effects of IL-17 remain unclear in the intestinal epithelium.
Hypoxia-Inducible Factor 1-Alpha Stabilizers in the Treatment of Inflammatory Bowel Diseases: Oxygen as a Novel IBD Therapy?
Shubha Bhat, Florian Rieder
doi : 10.1093/ecco-jcc/jjac092
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1924–1932
Despite the significant advances in the medical armamentarium for inflammatory bowel diseases [IBD], current treatment options have notable limitations.
Psychiatric Disorders in Adult and Paediatric Patients With Inflammatory Bowel Diseases – A Systematic Review and Meta-Analysis
Laura Arp, Sabine Jansson, Vibeke Wewer, Johan Burisch
doi : 10.1093/ecco-jcc/jjac095
Journal of Crohn's and Colitis, Volume 16, Issue 12, December 2022, Pages 1933–1945
Inflammatory bowel diseases [IBD], which are associated with a high disease burden, are also reported to be accompanied by a high prevalence of psychiatric disorders. However, the literature on IBD and psychiatric disorders has not been reviewed.
